Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Fera Pharmaceuticals
Acne Pipeline Yields Three Disappointments, One Win So Far In 2017
The pipeline of acne therapeutics is packed with possibilities, but of four candidates to report data so far this year, only one was successful – Allergan's and Paratek's sarecycline, which may be a better antibiotic option, but doesn't give dermatologists a much-needed new mechanism of action.
Start-Up Quarterly Statistics, Q4 2016
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.
Venture Funding Deals: ADC Therapeutics, Unity Biotech Raise $100m-Plus
ADC Therapeutics and Unity Biotechnology close $100m-plus VC rounds, while Carrick comes close with a $95m debut. Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging biopharmaceutical companies that have received venture funding. This month’s column covers deals announced in September and October 2016.
VC Roundup: October Brings Several New Venture Funds, Including Third Rock’s Fourth
Third Rock closed a $616m venture capital fund, exceeding the firm’s goal of $600m to fund newly formed biopharma companies, following Sofinnova and others with new VC and debt funds for early- to mid-stage life science companies. Also, five drug developers raised $256m in new VC cash.
- Generic Drugs
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.